Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Dystrophin (DMD) - Pipeline Review, H2 2019

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Dystrophin (DMD) - Pipeline Review, H2 2019

Dystrophin (DMD) - Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It act as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma.

Dystrophin (DMD) pipeline Target constitutes close to 48 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 4, 1, 23 and 12 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Musculoskeletal Disorders which include indications Duchenne Muscular Dystrophy and Muscular Dystrophy.

The latest report Dystrophin (DMD) - Pipeline Review, H2 2019, outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
- The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD)
- The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects
- The report assesses Dystrophin (DMD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Dystrophin (DMD) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Dystrophin (DMD)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dystrophin (DMD) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

TABLE OF CONTENTS

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dystrophin (DMD) - Overview
Dystrophin (DMD) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Dystrophin (DMD) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dystrophin (DMD) - Companies Involved in Therapeutics Development
Alpha Anomeric
Audentes Therapeutics Inc
Daiichi Sankyo Co Ltd
Dystrogen Therapeutics SA
Editas Medicine Inc
Evox Therapeutics Ltd
MyoGene Bio LLC
Nippon Shinyaku Co Ltd
NS Pharma Inc
OliPass Corporation
Pepgen Ltd
Pfizer Inc
Sarepta Therapeutics Inc
Spinalcyte Llc
Sutura Therapeutics Ltd
Tolerion Inc
Vertex Pharmaceuticals Inc
Wave Life Sciences Ltd
Dystrophin (DMD) - Drug Profiles
Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-753 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
casimersen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYMD-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMD-1742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-5141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eteplirsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Dystrophin for Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
golodirsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides 1 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides 3 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides 5 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides 6 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06939926 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Target Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-4008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-4044 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-4052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-4055 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-5044 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-5045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-5050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-5051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-5052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-5053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRP-9001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy 1 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy 2 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
viltolarsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dystrophin (DMD) - Dormant Products
Dystrophin (DMD) - Discontinued Products
Dystrophin (DMD) - Product Development Milestones
Featured News & Press Releases
Dec 13, 2019: Sareptas DMD therapy Vyondys 53 secures FDA accelerated approval
Nov 05, 2019: Dystrogen Therapeutics announces that treatment with Dystrophin expressing Chimeric (DEC) Cells improves cardiac function in Preclinical Duchennes Study
Aug 21, 2019: Sarepta fails to receive FDA approval for DMD drug golodirsen
Aug 08, 2019: Sarepta Therapeutics comments on erroneous submission to US FDA Adverse Event Reporting System (FAERS)
Jul 09, 2019: New analysis shows drug slows down respiratory decline
Jul 01, 2019: AskBios Perspective on Pfizers 1b clinical trial results on Duchenne MD Gene
Jun 28, 2019: Pfizer presents initial clinical data on phase 1b gene therapy study for Duchenne Muscular Dystrophy (DMD)
Apr 18, 2019: Parent Project Muscular Dystrophy awards $100,000 grant to Nationwide Childrens Hospital to further explore GALGT2 gene therapy in duchenne muscular dystrophy
Mar 28, 2019: Sarepta Therapeutics announces positive expression results from the Casimersen (SRP-4045) arm of the ESSENCE study
Mar 25, 2019: Sarepta Therapeutics to provide update on Duchenne Muscular Dystrophy gene therapy program
Feb 15, 2019: FDA accepts Sareptas NDA for precision medicine Golodirsen
Feb 06, 2019: NS Pharma begins rolling NDA submission to FDA for Viltolarsen (NS-065/NCNP-01)
Dec 20, 2018: Sarepta Therapeutics completes Submission of New Drug Application Seeking approval of Golodirsen (SRP-4053) in patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
Nov 13, 2018: Evox Therapeutics wins funding from Duchenne UK to explore exosome-mediated delivery of dystrophin
Oct 03, 2018: NS-065/NCNP-01 (Viltolarsen) of Nippon Shinyaku in-house product presentation on results of Phase I/II study in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Alpha Anomeric, H2 2019
Pipeline by Audentes Therapeutics Inc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Dystrogen Therapeutics SA, H2 2019
Pipeline by Editas Medicine Inc, H2 2019
Pipeline by Evox Therapeutics Ltd, H2 2019
Pipeline by MyoGene Bio LLC, H2 2019
Pipeline by Nippon Shinyaku Co Ltd, H2 2019
Pipeline by NS Pharma Inc, H2 2019
Pipeline by OliPass Corporation, H2 2019
Pipeline by Pepgen Ltd, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Sarepta Therapeutics Inc, H2 2019
Pipeline by Spinalcyte Llc, H2 2019
Pipeline by Sutura Therapeutics Ltd, H2 2019
Pipeline by Tolerion Inc, H2 2019
Pipeline by Vertex Pharmaceuticals Inc, H2 2019
Pipeline by Wave Life Sciences Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

List Of Figures

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

RELATED REPORTS

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Dystrophin (DMD) - Pipeline Review, H2 2019

Dystrophin (DMD) - Drugs In Development, 2021

Utrophin (Dystrophin Related Protein 1 or DRP1 or UTRN) - Drugs in Development, 2021

Dystrophin (DMD) - Drugs In Development, 2021

Dystrophin (DMD) - Pipeline Review, H2 2017

FAQs